Chief Executive Officer, ICON plc
Expertise: The Global Clinical Research Market
Dr. Steve Cutler was appointed Chief Executive Officer of ICON in March, 2017. Steve has over 23 years’ experience within the pharmaceutical and CRO industry and joined ICON from Kendle where he held the position of Chief Executive Officer, having previously served as Kendle’s Chief Operating Officer. Prior to Kendle, Steve spent 14 years with Quintiles where he served as Senior Vice President, Global Project Management; Senior Vice President, Clinical, Medical and Regulatory; Senior Vice President, Project Management - Europe; and Vice President, Oncology - Europe as well as regional leadership positions in South Africa and Australia. Prior to joining Quintiles, Steve held positions with Sandoz (now Novartis) in Australia and Europe.
Recent media contributions:
- A Medicircle article explaining how ICON was involved from the very first steps of the COVID-19 clinical trial supporting Pfizer‘s and BioNTech’s implementation of a strategic plan and framework for the monitoring of the trial.
- In Pink Sheet, ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post- pandemic.
Dr. Nuala Murphy
President of ICON Clinical Services
Expertise: COVID-19 clinical operations
Dr. Nuala Murphy has been President of ICON Clinical Services at ICON since January 2014. Prior to this, Dr. Murphy served as Executive Vice President of clinical and data operations globally. Dr. Murphy has over 20 years’ experience within the pharmaceutical and CRO industry. Dr. Murphy joined ICON in 2012 from Quintiles where she led a clinical and data management workforce (since 2009). Dr. Murphy also has over a decade of experience in therapeutics having led the CNS and internal medicine project management divisions for Quintiles. Dr. Murphy served in the field of late phase clinical research at Benefit International. During her tenure, Dr. Murphy published extensively in eminent peer reviewed journals. Having graduated from Trinity College Dublin, Dr. Murphy was awarded a PhD in neurochemistry, from the Department of Cardiovascular Studies in Leeds and conducted post-doctoral research in the Department of Neuropharmacology at the Collège de France in Paris.
Recent media contributions:
- Dr. Nuala Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale in this Contract Pharma article.
- How to run a coronavirus vaccine trial in a global pandemic. Dr. Murphy discusses in this Politico article, ICON’s experience with the Pfizer/BioNTech COVID-19 vaccine, the world’s first COVID-19 vaccine to achieve Emergency Use Authorisation.
Vaccine trials were run to the highest regulatory standards. Dr. Nuala Murphy explains in the Sunday Business Post.
Chief Information Officer
Prior to this he held the position of Global Head of Data Management at ICON Clinical Research. He joined the company in Feb-2001 as Manager of Data management in Dublin. He subsequently went on to set-up ICON's process improvement initiative "IMPROVE" and returned to Data Management to become EU VP of Data Management before becoming Global Head of Data Management in 2006.
Recent media contributions:
- A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
ICON’s CIO, Tom Leary discusses in this GBR article the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
Ms. Kim Boericke
President of ICON Commercialisation and Outcomes Services
Ms. Kim Boericke was appointed President of ICON Commercialisation and Outcomes Services in January 2019, having previously served as Executive Vice President, Global Program Management since 2014, where she was responsible for a number of therapeutic units (Oncology, Cardiovascular/Metabolic Diseases, CNS and Aging Diseases, Rare Diseases, Infectious Disease and Vaccines, Internal Medicine and Immunosciences, and Biosimilars). Prior to joining ICON, Ms. Boericke held positions with several clinical research organisations (CROs), including ClinTrials, Quintiles, INC Research, Duke Clinical Research Institute, and i3. She started as a Project Manager and moved her way up into jobs with more responsibility covering Program Management, Monitoring, Feasibility and Start Up, Functional Outsourcing, and Account Management running regions and global operations. She has extensive experience in managing drug development from Phase I through post marketing. Ms. Boericke graduated with a Bachelor of Science degree from Duke University in 1989.
Mr. Barry Balfe
President of ICON Functional Services
Expertise: Resourcing for Clinical Trials
Mr. Barry Balfe is President of ICON Functional Services (IFS). Mr. Balfe has been with ICON for over fifteen years and has held a number of senior roles, predominantly within the DOCS organisation, where he has successfully grown this business and has developed and led a number of new strategic partnerships. Mr. Balfe was previously EVP, Global Business Development. As part of the DOCS team, Mr. Balfe served as Senior Vice-President, Global Program Management where he oversaw operational design, planning & delivery within DOCS' resourcing & FSP businesses. He initially joined ICON’s Business Development team in 2003, before taking on the leadership of DOCS' US Business in early 2007 and subsequently overseeing DOCS' European Operations. Mr. Balfe holds a Bachelor of Science degree in chemistry, having studied at Dublin City University and Ecole Nationale Supérieure de Chimie de Toulouse. He subsequently studied pharmacoepidemiology and pharmacovigilance at London School of Hygiene and Tropical Medicine, the University of London.